Madrigal Pharmaceuticals
MDGL
148 hedge funds and large institutions have $2.27B invested in Madrigal Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 63 funds opening new positions, 47 increasing their positions, 34 reducing their positions, and 14 closing their positions.
541% more call options, than puts
Call options by funds: $55.4M | Put options by funds: $8.65M
350% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 14
207% more capital invested
Capital invested by funds: $739M → $2.27B (+$1.53B)
48% more funds holding
Funds holding: 100 → 148 (+48)
38% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 34
8.81% more ownership
Funds ownership: 44.46% → 53.27% (+8.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$97.2M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$86M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$67.1M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$65.6M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$35.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$31.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$27.6M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
-$23.4M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$21.1M |
MDGL Hedge Fund Activity: Q2 2018 in Review
148 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q2 2018, worth a combined $2.27B — up 207% from $739M a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new MDGL positions and 14 closed out — a net gain of 49 holders — while 47 added to existing stakes and 34 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $97.2M. The largest seller was Adage Capital Partners, cutting an estimated $35.1M.
- 148 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q2 2018, up from 100 in Q1 2018.
- Funds reported $2.27B of Madrigal Pharmaceuticals stock for Q2 2018, up 207% quarter-over-quarter.
- 63 funds opened new Madrigal Pharmaceuticals positions in Q2 2018 and 14 closed out, a net change of +49 holders.
- The largest Madrigal Pharmaceuticals buyer in Q2 2018 was Baker Bros. Advisors, an estimated $97.2M added.
- The largest Madrigal Pharmaceuticals seller in Q2 2018 was Adage Capital Partners, an estimated $35.1M sold.
Based on aggregated 13F filings for Q2 2018.